Product Name: KinSub2DDLYY
Product Number: PE-01AJW95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub2DDLYY

Product Use: For assaying the phosphotransferase activity of Fer (fps/fes related) protein-tyrosine kinase (UniProt ID P16591). The KinSub2DDLYY peptide demonstrated medium phosphotransferase activity with Brk, and exhibited medium specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub2DDLYY was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: GGGEDDLYYCVCGGY

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1569.7 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Brk

Scientific Background: Fer is one of several protein kinases that can phosphorylate KinSub2DDLYY. Human Fer is a protein-tyrosine kinase of 822 amino acid length, with a predicted molecular mass of 94,638 Da. It is a member of the TK group of protein kinases in the Fer family. This kinase is moderate to highly expressed in most tested human tissues. Orthologues of Fer are highly conserved in vertebrates and insects. Fer is a member of the Fps/Fes family of nontransmembrane receptor tyrosine kinases. Fer plays a role in regulating cytoskeletal rearrangements and inside out signalling that accompany receptor ligand, cell matrix and cell cell interactions (1). Genetic analysis using transgenic mouse models implicate Fer in the regulation of inflammation and innate immunity. Fer-deficient mice displayed enhanced recruitment of leukocytes in response to local LPS challenge. Fer is required for cell-cycle progression in malignant cells. Decreasing the level of Fer using RNAi impeded the proliferation of prostate and breast carcinoma cells and led to their arrest at the G0/G1 phase (2). Fer has been linked with the development of prostate cancer and lung small cell carcinomas (LSCC).